Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advanced pancreatic cancer undergoing chemotherapy

International Journal of Cancer

Volumn 133, Issue 11, 2013, Pages 2619-2630

  Wittwer, Christin ^a   Boeck, Stefan ^a   Heinemann, Volker ^a   Haas, Michael ^a   Stieber, Petra ^a   Nagel, Dorothea ^a   Holdenrieder, Stefan ^a,b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

DNAse activity; HMBG1; nucleosomes; pancreatic cancer; prognosis; sRAGE

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AXITINIB; CAPECITABINE; DEOXYRIBONUCLEASE; ERLOTINIB; EVEROLIMUS; GEMCITABINE; HIGH MOBILITY GROUP B1 PROTEIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOGENICITY; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; NUCLEOSOME; OVERALL SURVIVAL; PANCREAS CANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

DNASE ACTIVITY; HMBG1; NUCLEOSOMES; PANCREATIC CANCER; PROGNOSIS; SRAGE;

ADULT; AGED; DEOXYRIBONUCLEASES; DISEASE-FREE SURVIVAL; FEMALE; HMGB1 PROTEIN; HUMANS; MALE; MIDDLE AGED; NUCLEOSOMES; PANCREATIC NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTORS, IMMUNOLOGIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84884909735     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28294     Document Type: Article

References (46)

1. World Health Organization. The global burden of disease. World Health Organization 2008. Available at: http://www.who.int/evidence/bod.
2. Siegel R, Naishadham D, Jemal A,. Cancer statistics 2012. CA Cancer J Clin 2012; 62: 10-29.
3. Heinemann V, Quietzsch D, Gieseler F, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006; 24: 3946-52.
4. Hochster HS, Haller DG, de Gramont A, et al. Consensus report of the international society of gastrointestinal oncology on therapeutic progress in advanced pancreatic cancer. Cancer 2006; 107: 676-85.
5. Cunningham D, Chau I, Stocken DD, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol 2009; 27: 5513-18.
6. Brambs HJ, Claussen CD,. Pancreatic and ampullary carcinoma. Ultrasound, computed tomography, magnetic resonance imaging and angiography. Endoscopy 1993; 25: 58-68.
7. Vincent A, Herman J, Schulick R, et al. Pancreatic cancer. Lancet 2011; 378: 607-20.
8. Boeck S, Haas M, Laubender RP, et al. Application of a time-varying covariate model to the analysis of CA 19-9 as serum biomarker in patients with advanced pancreatic cancer. Clin Cancer Res 2010; 16: 986-94.
9. Boeck S, Stieber P, Holdenrieder S, et al. Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer. Oncology 2006; 70: 255-64.
10. Haas M, Laubender RP, Stieber P, et al. Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer. Tumor Biol 2010; 31: 351-7.
11. Kremer A, Wilkowski R, Holdenrieder S, et al. Nucleosomes in pancreatic cancer patients during radiochemotherapy. Tumor Biol 2005; 26: 44-9.
12. Holdenrieder S, Stieber P,. Therapy control in oncology by circulating nucleosomes. Ann N Y Acad Sci 2004; 1022: 211-16.
13. Holdenrieder S, Stieber P, von Pawel J, et al. Early and specific prediction of the therapeutic efficacy in non-small cell lung cancer patients by nucleosomal DNA and cytokeratin-19 fragments. Ann N Y Acad Sci 2006; 1075: 244-57.
14. Kremer A, Holdenrieder S, Stieber P, et al. Nucleosomes in colorectal cancer patients during radiochemotherapy. Tumor Biol 2006; 27: 235-42.
15. Kohles N, Nagel D, Jungst D, et al. Relevance of circulating nucleosomes and oncological biomarkers for predicting response to transarterial chemoembolization therapy in liver cancer patients. BMC Cancer 2011; 11: 202.
16. Kumar S, Guleria R, Singh V, et al. Plasma nucleosome levels might predict response to therapy in patients with advanced non-small-cell lung cancer. Clin Lung Cancer 2010; 11: 36-44.
17. Fahmueller Y, Nagel D, Hoffmann RT, et al. Predictive and prognostic value of circulating nucleosomes and serum biomarkers in patients with metastasized colorectal cancer undergoing Selective Internal Radiation Therapy. BMC Cancer 2012; 12: 5.
18. Peitsch MC, Hesterkamp T, Polzar B, et al. Functional characterisation of serum DNase I in MRL-lpr/lpr mice. Biochem Biophys Res Commun 1992; 186: 739-45.
19. Kepp O, Galluzzi L, Martins I, et al. Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev 2011; 30: 61-9.
20. Apetoh L, Ghiringhelli F, Tesniere A, et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev 2007; 220: 47-59.
21. Tang D, Kang R, Zeh HJ, III, et al. High-mobility group box 1 and cancer. Biochim Biophys Acta 2010; 1799: 131-40.
22. Cavallo F, De Giovanni C, Nanni P, et al. The immune hallmarks of cancer. Cancer Immunol Immunother 2011; 60: 319-26.
23. Bianchi ME, Manfredi AA,. High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol Rev 2007; 220: 35-46.
24. Gong H, Zuliani P, Komuravelli A, et al. Analysis and verification of the HMGB1 signaling pathway. BMC Bioinformatics 2010; 11: S10.
25. Tesniere A, Panaretakis T, Kepp O, et al. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ 2008; 15: 3-12.
26. Zitvogel L, Kepp O, Kroemer G,. Decoding cell death signals in inflammation and immunity. Cell 2010; 140: 798-804.
27. Kuniyasu H, Oue N, Wakikawa A, et al. Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol 2002; 196: 163-70.
28. Sasahira T, Akama Y, Fujii K, et al. Expression of receptor for advanced glycation end products and HMGB1/amphoterin in colorectal adenomas. Virchows Arch 2005; 446: 411-15.
29. Kang R, Tang D, Schapiro NE, et al. The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival. Cell Death Differ 2009; 17: 666-76.
30. Geroldi D, Falcone C, Emanuele E,. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr Med Chem 2006; 13: 1971-8.
31. Holdenrieder S, Stieber P, Bodenmuller H, et al. Nucleosomes in serum as a marker for cell death. Clin Chem Lab Med 2001; 39: 596-605.
32. Holdenrieder S, Stieber P, Chan LY, et al. Cell-free DNA in serum and plasma: comparison of ELISA and quantitative PCR. Clin Chem 2005; 51: 1544-6.
33. Wittwer C, Lehner J, Fersching D, et al. Methodological and preanalytical evaluation of a RAGE immunoassay. Anticancer Res 2012; 32: 2075-8.
34. Lehner J, Wittwer C, Fersching D, et al. Methodical validation of an immunoassay for the determination of soluble high mobility group box 1 (sHMGB1). Anticancer Res 2012; 32: 2059-62.
35. Harrell FE, Jr, Lee KL, Califf RM, et al. Regression modelling strategies for improved prognostic prediction. Stat Med 1984; 3: 143-52.
36. Heinemann V, Boeck S, Hinke A, et al. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 2008; 8: 82.
37. Naumnik W, Nilklinska W, Ossolinska M, et al. Serum levels of HMGB1, survivin, and VEGF in patients with advanced non-small cell lung cancer during chemotherapy. Folia Histochem Cytobiol 2009; 47: 703-9.
38. Shang GH, Jia CQ, Tian H, et al. Serum high mobility group box protein 1 as a clinical marker for non-small cell lung cancer. Respir Med 2009; 103: 1949-53.
39. Cheng BQ, Jia CQ, Liu CT, et al. Serum high mobility group box chromosomal protein 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma. Dig Liver Dis 2008; 40: 446-52.
40. Sheng X, Du X, Zhang X, et al. Clinical value of serum HMGB1 levels in early detection of recurrent squamous cell carcinoma of uterine cervix: comparison with serum SCCA, CYFRA21-1, and CEA levels. Croatian Med J 2009; 50: 455-64.
41. Fahmueller Y, Nagel D, Hoffmann RT, et al. Immunogenic cell death biomarkers HMGB1, RAGE and DNAse indicate response to Selective Internal Radiation Therapy in colorectal cancer patients. Int J Cancer 2013; 132: 2349-58.
42. Bell CW, Jiang W, Reich CF, III, et al. The extracellular release of HMGB1 during apoptotic cell death. Am J Physiol Cell Physiol 2006; 291: 1318-25.
43. Dong Xda E, Ito N, Lotze MT, et al. High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. J Immunother 2007; 30: 596-606.
44. Kohles N, Nagel D, Jüngst D, et al. Predictive and prognostic value of immunogenic cell death biomarkers HMGB1, sRAGE and DNAse in liver cancer patients receiving transarterial chemoembolization therapy. Tumor Biol 2012; 33: 2401-9.
45. Boeck S, Wittwer C, Heinemann V, et al. Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer. Br J Cancer 2013; 108: 1684-94.
46. Stoetzer OJ, Wittwer C, Lehner J, et al. Circulating nucleosomes and biomarkers of immunogenic cell death as predictive and prognostic markers in cancer patients undergoing cytotoxic therapy. Expert Opin Biol Ther 2012; 12: S217-S224.